Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  3/9/2018
Allison Cancer Center
mi
from
Midland, TX
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 3/9/2018
Allison Cancer Center
mi
from
Midland, TX
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  3/9/2018
Texas Oncology-Paris
mi
from
Paris, TX
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 3/9/2018
Texas Oncology-Paris
mi
from
Paris, TX
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  3/9/2018
Texas Oncology-Tyler
mi
from
Tyler, TX
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 3/9/2018
Texas Oncology-Tyler
mi
from
Tyler, TX
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  3/9/2018
Texas Oncology - Deke Slayton Cancer Center
mi
from
Webster, TX
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 3/9/2018
Texas Oncology - Deke Slayton Cancer Center
mi
from
Webster, TX
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  3/9/2018
Texas Oncology-Texoma Cancer Center
mi
from
Wichita Falls, TX
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 3/9/2018
Texas Oncology-Texoma Cancer Center
mi
from
Wichita Falls, TX
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  3/9/2018
Veterans Education and Research Association of Northern New England, Inc.
mi
from
White River Junction, VT
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 3/9/2018
Veterans Education and Research Association of Northern New England, Inc.
mi
from
White River Junction, VT
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  3/9/2018
Cancer Outreach Associates, PC
mi
from
Abingdon, VA
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 3/9/2018
Cancer Outreach Associates, PC
mi
from
Abingdon, VA
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  3/9/2018
Fairfax-Northern Virginia Hematology Oncology, PC
mi
from
Fairfax, VA
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 3/9/2018
Fairfax-Northern Virginia Hematology Oncology, PC
mi
from
Fairfax, VA
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  3/9/2018
Virginia Oncology Associates
mi
from
Norfolk, VA
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 3/9/2018
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  3/9/2018
Oncology and Hematology Associates of Southwest Virginia
mi
from
Roanoke, VA
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 3/9/2018
Oncology and Hematology Associates of Southwest Virginia
mi
from
Roanoke, VA
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  3/9/2018
VA Puget Sound HCS Seattle Division
mi
from
Seattle, WA
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 3/9/2018
VA Puget Sound HCS Seattle Division
mi
from
Seattle, WA
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  3/9/2018
Royal Adelaide Hospital
mi
from
Adelaide,
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 3/9/2018
Royal Adelaide Hospital
mi
from
Adelaide,
Click here to add this to my saved trials
Efficacy of Cancer Support Programs: A Social Comparison Theory Analysis
Efficacy of Cancer Support Programs: A Social Comparison Theory Analysis
Status: Enrolling
Updated:  3/13/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Efficacy of Cancer Support Programs: A Social Comparison Theory Analysis
Efficacy of Cancer Support Programs: A Social Comparison Theory Analysis
Status: Enrolling
Updated: 3/13/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
A Phase I/II Trial of AEZS-108 in Locally Advanced Unresectable or Metastatic Luteinizing Hormone-releasing Hormone(LHRH) Positive Urothelial Carcinoma Patients Who Failed Platinum Based Chemotherapy
Status: Enrolling
Updated:  3/13/2018
University of Miami Miller School of Medicine
mi
from
Miami, FL
A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
A Phase I/II Trial of AEZS-108 in Locally Advanced Unresectable or Metastatic Luteinizing Hormone-releasing Hormone(LHRH) Positive Urothelial Carcinoma Patients Who Failed Platinum Based Chemotherapy
Status: Enrolling
Updated: 3/13/2018
University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
A Phase I/II Trial of AEZS-108 in Locally Advanced Unresectable or Metastatic Luteinizing Hormone-releasing Hormone(LHRH) Positive Urothelial Carcinoma Patients Who Failed Platinum Based Chemotherapy
Status: Enrolling
Updated:  3/13/2018
Univerity of Pennsylvania
mi
from
Philadelphia, PA
A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
A Phase I/II Trial of AEZS-108 in Locally Advanced Unresectable or Metastatic Luteinizing Hormone-releasing Hormone(LHRH) Positive Urothelial Carcinoma Patients Who Failed Platinum Based Chemotherapy
Status: Enrolling
Updated: 3/13/2018
Univerity of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer
A Multidisciplinary Team-Based Approach to Mitigate the Impact of Androgen Deprivation Therapy in Prostate Cancer: A Randomized Phase 2
Status: Enrolling
Updated:  3/13/2018
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer
A Multidisciplinary Team-Based Approach to Mitigate the Impact of Androgen Deprivation Therapy in Prostate Cancer: A Randomized Phase 2
Status: Enrolling
Updated: 3/13/2018
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Click here to add this to my saved trials
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/13/2018
University of Colorado Health Sciences Center (UCHSC)
mi
from
Aurora, CO
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/13/2018
University of Colorado Health Sciences Center (UCHSC)
mi
from
Aurora, CO
Click here to add this to my saved trials
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/13/2018
Recruiting
mi
from
Rockville, MD
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/13/2018
Recruiting
mi
from
Rockville, MD
Click here to add this to my saved trials
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/13/2018
Recruiting
mi
from
San Francisco, CA
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/13/2018
Recruiting
mi
from
San Francisco, CA
Click here to add this to my saved trials
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/13/2018
Recruiting
mi
from
Towson, MD
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/13/2018
Recruiting
mi
from
Towson, MD
Click here to add this to my saved trials
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/13/2018
Recrutiing
mi
from
Philadelphia, PA
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/13/2018
Recrutiing
mi
from
Philadelphia, PA
Click here to add this to my saved trials
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/13/2018
Recruiting
mi
from
Providence, RI
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/13/2018
Recruiting
mi
from
Providence, RI
Click here to add this to my saved trials
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/13/2018
Clinical Research Facility
mi
from
New Brunswick, NJ
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/13/2018
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/13/2018
Site
mi
from
Philadelphia, PA
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/13/2018
Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Active Surveillance in Prostate Cancer
Active Surveillance in Prostate Cancer: A Prospective Cohort Study
Status: Enrolling
Updated:  3/14/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Active Surveillance in Prostate Cancer
Active Surveillance in Prostate Cancer: A Prospective Cohort Study
Status: Enrolling
Updated: 3/14/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy
Phase II Trial of B-DIM (DIM: 3,3 Diindolylmethane) on Intermediate Endpoint Biomarkers in Patients With Prostate Cancer Who Are Undergoing Prostatectomy
Status: Enrolling
Updated:  3/14/2018
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy
Phase II Trial of B-DIM (DIM: 3,3 Diindolylmethane) on Intermediate Endpoint Biomarkers in Patients With Prostate Cancer Who Are Undergoing Prostatectomy
Status: Enrolling
Updated: 3/14/2018
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy
Phase II Trial of B-DIM (DIM: 3,3 Diindolylmethane) on Intermediate Endpoint Biomarkers in Patients With Prostate Cancer Who Are Undergoing Prostatectomy
Status: Enrolling
Updated:  3/14/2018
Josephine Ford Cancer Center at Henry Ford Hospital
mi
from
Detroit, MI
Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy
Phase II Trial of B-DIM (DIM: 3,3 Diindolylmethane) on Intermediate Endpoint Biomarkers in Patients With Prostate Cancer Who Are Undergoing Prostatectomy
Status: Enrolling
Updated: 3/14/2018
Josephine Ford Cancer Center at Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
Arizona Oncology Services Foundation
mi
from
Phoenix, AZ
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
Arizona Oncology Services Foundation
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
Arizona Oncology - Tucson
mi
from
Tucson, AZ
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
Arizona Oncology - Tucson
mi
from
Tucson, AZ
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
Auburn Radiation Oncology
mi
from
Auburn, CA
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
Auburn Radiation Oncology
mi
from
Auburn, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
Alta Bates Summit Comprehensive Cancer Center
mi
from
Berkeley, CA
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
Alta Bates Summit Comprehensive Cancer Center
mi
from
Berkeley, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
Providence Saint Joseph Medical Center - Burbank
mi
from
Burbank, CA
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
Providence Saint Joseph Medical Center - Burbank
mi
from
Burbank, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
Peninsula Medical Center
mi
from
Burlingame, CA
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
Peninsula Medical Center
mi
from
Burlingame, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
Radiation Oncology Centers - Cameron Park
mi
from
Cameron Park, CA
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
Radiation Oncology Centers - Cameron Park
mi
from
Cameron Park, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
Mercy Cancer Center at Mercy San Juan Medical Center
mi
from
Carmichael, CA
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
Mercy Cancer Center at Mercy San Juan Medical Center
mi
from
Carmichael, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
East Bay Radiation Oncology Center
mi
from
Castro Valley, CA
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
East Bay Radiation Oncology Center
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
Valley Medical Oncology Consultants - Castro Valley
mi
from
Castro Valley, CA
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
Valley Medical Oncology Consultants - Castro Valley
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
Valley Medical Oncology
mi
from
Fremont, CA
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
Valley Medical Oncology
mi
from
Fremont, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
Marin Cancer Institute at Marin General Hospital
mi
from
Greenbrae, CA
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
Marin Cancer Institute at Marin General Hospital
mi
from
Greenbrae, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
Sutter Health Western Division Cancer Research Group
mi
from
Greenbrae, CA
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
Sutter Health Western Division Cancer Research Group
mi
from
Greenbrae, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
Kaiser Permanente Medical Center - Hayward
mi
from
Hayward, CA
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
Kaiser Permanente Medical Center - Hayward
mi
from
Hayward, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
Veterans Affairs Medical Center - Long Beach
mi
from
Long Beach, CA
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
Veterans Affairs Medical Center - Long Beach
mi
from
Long Beach, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
Kaiser Permanente Medical Center - Los Angeles
mi
from
Los Angeles, CA
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
Kaiser Permanente Medical Center - Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
Alta Bates Summit Medical Center - Summit Campus
mi
from
Oakland, CA
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
Alta Bates Summit Medical Center - Summit Campus
mi
from
Oakland, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
Bay Area Breast Surgeons, Incorporated
mi
from
Oakland, CA
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
Bay Area Breast Surgeons, Incorporated
mi
from
Oakland, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
CCOP - Bay Area Tumor Institute
mi
from
Oakland, CA
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
CCOP - Bay Area Tumor Institute
mi
from
Oakland, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
Larry G Strieff MD Medical Corporation
mi
from
Oakland, CA
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
Larry G Strieff MD Medical Corporation
mi
from
Oakland, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
Tom K Lee, Incorporated
mi
from
Oakland, CA
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
Tom K Lee, Incorporated
mi
from
Oakland, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
Kaiser Permanente - Division of Research - Oakland
mi
from
Oakland, CA
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
Kaiser Permanente - Division of Research - Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated:  3/14/2018
Kaiser Permanente Medical Center - Oakland
mi
from
Oakland, CA
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Status: Enrolling
Updated: 3/14/2018
Kaiser Permanente Medical Center - Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials